-
Roche Announces Phase II Open-Label SHIELD DMD Study to Assess Effect of Satralizumab on Bone Health in Duchenne
Today Roche announced plans for the SHIELD DMD study, a phase II open-label study to […]
-
During a busy season, we must take things one day at a time
I feel relaxed — refreshed, even. We’ve had almost two weeks at home without any […]
-
Summer Fun: Accessible Activities for All Ages and Interests
As the school year wraps up, we are all looking forward to a fun-filled […]
-
Advisory board named to shepherd Duchenne MD candidate
Satellos Bioscience has established a clinical advisory board, with experts in drug development and genetic […]
-
Three years of CAP-1002 still stabilizing arm, heart function
After three years of treatment with Capricor Therapeutics’ experimental cell therapy CAP-1002, people with Duchenne […]
-
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002
Capricor Therapeutics has announced positive 3-year results from the ongoing HOPE-2 open-label extension (OLE) study […]
-
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
Read the full news release HERE Capricor Therapeutics, which received early funding from CureDuchenne, has […]
-
What’s it like to have three sons living with DMD?
What’s it like to have three children with Duchenne muscular dystrophy (DMD)? That’s the question […]
-
I tried home health physical therapy, but will I keep exercising?
In a column I wrote last month, I talked about finally deciding to try some […]
-
Engineered tRNA fixes faulty dystrophin protein in DMD mice
An engineered transfer RNA (tRNA) molecule developed by hC Bioscience could be a fix for […]
